Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología
Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with Inter...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Tagungsbericht |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | |
| container_volume | 34 |
| creator | Castiñeiras Fernández, J Cozar Olmo, J M Fernández-Pro, A Martín, J A Brenes Bermúdez, F J Naval Pulido, E Molero, J M Pérez Morales, D |
| description | Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA |
| format | Conference Proceeding |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733889092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733889092</sourcerecordid><originalsourceid>FETCH-LOGICAL-p550-4eaef207cc09048bc0b2c6ae1d52529af4a1a3f30ddfa1370bd4446f1c63877b3</originalsourceid><addsrcrecordid>eNqFkb9OwzAQxiMkREvhFZA3FoocO3_HqmoLUhEIyhxd7EsxSuJgJ0MfiYEB8Qh5LQZcWgYGxHQn3fe7-_TdgTf0ozQdx2lCB96xtc-UsoAn8ZE3YJQx7nM69D7vsUBjoCTCqBaNAlJoQ3Ks1bomjdG2hVYJ8rRp0DQlWCdQ24GqwGyIAIOXD1oolCDJzDbQv-sSiERy079KJbTd9pMWa6H6j5rcfYMKLsgfFDpI1UAWWKOz9a_O9XOoVOl8bchUV12t2t2BiXUk7M7-Yh-NLvW6f4MT77CA0uLpvo681Xy2ml6Nl7eL6-lkOW7CkI4DBCwYjYWgKQ2SXNCciQjQlyELWQpFAD7wglMpC_B5THMZBEFU-CJyacc5H3nnu7UuzpcObZtVygosS6hRdzaLOU-SlKbMKc_2yi6vUGb7mLOff_Ev3kabJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>conference_proceeding</recordtype><pqid>733889092</pqid></control><display><type>conference_proceeding</type><title>Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Castiñeiras Fernández, J ; Cozar Olmo, J M ; Fernández-Pro, A ; Martín, J A ; Brenes Bermúdez, F J ; Naval Pulido, E ; Molero, J M ; Pérez Morales, D</creator><creatorcontrib>Castiñeiras Fernández, J ; Cozar Olmo, J M ; Fernández-Pro, A ; Martín, J A ; Brenes Bermúdez, F J ; Naval Pulido, E ; Molero, J M ; Pérez Morales, D ; Sociedad Española de Médicos de Atención Primaria ; Sociedad Española de Medicina de Familia y Comunitaria ; Asociación Española de Urología ; Sociedad Española de Medicina General</creatorcontrib><description>Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.</description><identifier>EISSN: 1699-7980</identifier><identifier>PMID: 20223130</identifier><language>spa</language><publisher>Spain</publisher><subject>5-alpha Reductase Inhibitors ; Adrenergic alpha-Antagonists - therapeutic use ; Aged ; Algorithms ; Diagnosis, Differential ; Disease Progression ; Enzyme Inhibitors - therapeutic use ; Humans ; Male ; Middle Aged ; Phytotherapy ; Primary Health Care ; Prostate-Specific Antigen - blood ; Prostatectomy - methods ; Prostatic Hyperplasia - blood ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - therapy ; Prostatic Neoplasms - diagnosis ; Prostatitis - diagnosis ; Referral and Consultation - standards</subject><ispartof>Actas urologicas españolas, 2010, Vol.34 (1), p.24-34</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20223130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castiñeiras Fernández, J</creatorcontrib><creatorcontrib>Cozar Olmo, J M</creatorcontrib><creatorcontrib>Fernández-Pro, A</creatorcontrib><creatorcontrib>Martín, J A</creatorcontrib><creatorcontrib>Brenes Bermúdez, F J</creatorcontrib><creatorcontrib>Naval Pulido, E</creatorcontrib><creatorcontrib>Molero, J M</creatorcontrib><creatorcontrib>Pérez Morales, D</creatorcontrib><creatorcontrib>Sociedad Española de Médicos de Atención Primaria</creatorcontrib><creatorcontrib>Sociedad Española de Medicina de Familia y Comunitaria</creatorcontrib><creatorcontrib>Asociación Española de Urología</creatorcontrib><creatorcontrib>Sociedad Española de Medicina General</creatorcontrib><title>Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología</title><title>Actas urologicas españolas</title><addtitle>Actas Urol Esp</addtitle><description>Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.</description><subject>5-alpha Reductase Inhibitors</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Algorithms</subject><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phytotherapy</subject><subject>Primary Health Care</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Hyperplasia - blood</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - therapy</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatitis - diagnosis</subject><subject>Referral and Consultation - standards</subject><issn>1699-7980</issn><fulltext>true</fulltext><rsrctype>conference_proceeding</rsrctype><creationdate>2010</creationdate><recordtype>conference_proceeding</recordtype><sourceid>EIF</sourceid><recordid>eNqFkb9OwzAQxiMkREvhFZA3FoocO3_HqmoLUhEIyhxd7EsxSuJgJ0MfiYEB8Qh5LQZcWgYGxHQn3fe7-_TdgTf0ozQdx2lCB96xtc-UsoAn8ZE3YJQx7nM69D7vsUBjoCTCqBaNAlJoQ3Ks1bomjdG2hVYJ8rRp0DQlWCdQ24GqwGyIAIOXD1oolCDJzDbQv-sSiERy079KJbTd9pMWa6H6j5rcfYMKLsgfFDpI1UAWWKOz9a_O9XOoVOl8bchUV12t2t2BiXUk7M7-Yh-NLvW6f4MT77CA0uLpvo681Xy2ml6Nl7eL6-lkOW7CkI4DBCwYjYWgKQ2SXNCciQjQlyELWQpFAD7wglMpC_B5THMZBEFU-CJyacc5H3nnu7UuzpcObZtVygosS6hRdzaLOU-SlKbMKc_2yi6vUGb7mLOff_Ev3kabJw</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Castiñeiras Fernández, J</creator><creator>Cozar Olmo, J M</creator><creator>Fernández-Pro, A</creator><creator>Martín, J A</creator><creator>Brenes Bermúdez, F J</creator><creator>Naval Pulido, E</creator><creator>Molero, J M</creator><creator>Pérez Morales, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología</title><author>Castiñeiras Fernández, J ; Cozar Olmo, J M ; Fernández-Pro, A ; Martín, J A ; Brenes Bermúdez, F J ; Naval Pulido, E ; Molero, J M ; Pérez Morales, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p550-4eaef207cc09048bc0b2c6ae1d52529af4a1a3f30ddfa1370bd4446f1c63877b3</frbrgroupid><rsrctype>conference_proceedings</rsrctype><prefilter>conference_proceedings</prefilter><language>spa</language><creationdate>2010</creationdate><topic>5-alpha Reductase Inhibitors</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Algorithms</topic><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phytotherapy</topic><topic>Primary Health Care</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Hyperplasia - blood</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - therapy</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatitis - diagnosis</topic><topic>Referral and Consultation - standards</topic><toplevel>online_resources</toplevel><creatorcontrib>Castiñeiras Fernández, J</creatorcontrib><creatorcontrib>Cozar Olmo, J M</creatorcontrib><creatorcontrib>Fernández-Pro, A</creatorcontrib><creatorcontrib>Martín, J A</creatorcontrib><creatorcontrib>Brenes Bermúdez, F J</creatorcontrib><creatorcontrib>Naval Pulido, E</creatorcontrib><creatorcontrib>Molero, J M</creatorcontrib><creatorcontrib>Pérez Morales, D</creatorcontrib><creatorcontrib>Sociedad Española de Médicos de Atención Primaria</creatorcontrib><creatorcontrib>Sociedad Española de Medicina de Familia y Comunitaria</creatorcontrib><creatorcontrib>Asociación Española de Urología</creatorcontrib><creatorcontrib>Sociedad Española de Medicina General</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castiñeiras Fernández, J</au><au>Cozar Olmo, J M</au><au>Fernández-Pro, A</au><au>Martín, J A</au><au>Brenes Bermúdez, F J</au><au>Naval Pulido, E</au><au>Molero, J M</au><au>Pérez Morales, D</au><aucorp>Sociedad Española de Médicos de Atención Primaria</aucorp><aucorp>Sociedad Española de Medicina de Familia y Comunitaria</aucorp><aucorp>Asociación Española de Urología</aucorp><aucorp>Sociedad Española de Medicina General</aucorp><format>book</format><genre>proceeding</genre><ristype>CONF</ristype><atitle>Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología</atitle><btitle>Actas urologicas españolas</btitle><addtitle>Actas Urol Esp</addtitle><date>2010-01</date><risdate>2010</risdate><volume>34</volume><issue>1</issue><spage>24</spage><epage>34</epage><pages>24-34</pages><eissn>1699-7980</eissn><abstract>Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.</abstract><cop>Spain</cop><pmid>20223130</pmid><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1699-7980 |
| ispartof | Actas urologicas españolas, 2010, Vol.34 (1), p.24-34 |
| issn | 1699-7980 |
| language | spa |
| recordid | cdi_proquest_miscellaneous_733889092 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | 5-alpha Reductase Inhibitors Adrenergic alpha-Antagonists - therapeutic use Aged Algorithms Diagnosis, Differential Disease Progression Enzyme Inhibitors - therapeutic use Humans Male Middle Aged Phytotherapy Primary Health Care Prostate-Specific Antigen - blood Prostatectomy - methods Prostatic Hyperplasia - blood Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - therapy Prostatic Neoplasms - diagnosis Prostatitis - diagnosis Referral and Consultation - standards |
| title | Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A49%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=proceeding&rft.atitle=Referral%20criteria%20for%20benign%20prostatic%20hyperplasia%20in%20primary%20care.Sociedad%20Espa%C3%B1ola%20de%20M%C3%A9dicos%20de%20Atenci%C3%B3n%20Primaria,%20Sociedad%20Espa%C3%B1ola%20de%20Medicina%20General,%20Sociedad%20Espa%C3%B1ola%20de%20Medicina%20de%20Familia%20y%20Comunitaria,%20Asociaci%C3%B3n%20Espa%C3%B1ola%20de%20Urolog%C3%ADa&rft.btitle=Actas%20urologicas%20espa%C3%B1olas&rft.au=Casti%C3%B1eiras%20Fern%C3%A1ndez,%20J&rft.aucorp=Sociedad%20Espa%C3%B1ola%20de%20M%C3%A9dicos%20de%20Atenci%C3%B3n%20Primaria&rft.date=2010-01&rft.volume=34&rft.issue=1&rft.spage=24&rft.epage=34&rft.pages=24-34&rft.eissn=1699-7980&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733889092%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733889092&rft_id=info:pmid/20223130&rfr_iscdi=true |